Vertex: Good News from Europe. Ablynx: Rejecting Novo Nordisk’s Aquisition Offers.

From Europe, Vertex (VRTX) was informed that the European Commission has granted an extension of the Marketing Authorization for ORKAMBI® (lumacaftor/ivacaftor).

Orkambi is for cystic fibrosis (CF) in people with two copies of the F508del mutation, including children ages 6 through 11

Reimbursement: In countries such as Ireland, reimbursement agreements will lead to rapid access to ORKAMBI. In other countries across the European Union, Vertex will begin a country-by-country reimbursement process.

Clinical trial Results demonstrated statistically significant 

This content is for paid subscribers.
Please click here to subscribe or here to log in.